No profile data available.
Agios Pharmaceuticals, Inc. (AGIO) is a healthcare company in the blood disorder treatment drugs industry, based in Cambridge, United States, with about 539 full-time employees.
It reported revenue of $54.03 million for fiscal year 2025, up 48.0% from fiscal year 2024, and net income of -$412.78 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $44.75 million, up 259.3% from a year before. Its market capitalization was $1.89 billion as of October 6, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 6, 2026.
, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Agios Pharmaceuticals reported $54.03 million in revenue for fiscal year 2025, up 48.0% from $36.50 million in fiscal year 2024. In Q2 2026 revenue was $44.75 million.
$1.89 billion as of October 6, 2026.
Listed companies of a similar size in the same industry (blood disorder treatment drugs) include Incyte Corporation (INCY), Protagonist Therapeutics, Inc. (PTGX), uniQure N.v. (QURE), Ultragenyx Pharmaceutical Inc. (RARE).